ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Kansas City, KS

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Kansas City, KS, USA:

Locations recently updated

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

binimetinib, and pembrolizumab) given together for the treatment of melanoma that:* is advanced or metastatic (spread to other parts of the ...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

Phase 3

Pfizer
Pfizer

Westwood, Kansas, United States and 227 other locations

alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...

Enrolling
Melanoma
Unresectable Melanoma
Biological: Pembrolizumab with Optional Crossover Period
Biological: Lifileucel plus Pembrolizumab

Phase 3

Iovance Biotherapeutics

Kansas City, Kansas, United States and 44 other locations

lymphodepletion and interleukin-2, work for treating patients with melanoma that cannot be removed by surgery (unresectable) or that has spr...

Enrolling
Clinical Stage IV Cutaneous Melanoma AJCC v8
Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Drug: Cyclophosphamide
Biological: Interleukin-2

Phase 2

University of Kansas
University of Kansas

Kansas City, Kansas, United States

to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...

Active, not recruiting
Melanoma
Biological: Nivolumab
Biological: Nivolumab + Relatlimab Fixed Dose Combination

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Westwood, Kansas, United States and 171 other locations

(Spartalizumab (PDR001)), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma...

Active, not recruiting
Melanoma
Drug: Trametinib
Drug: Dabrafenib

Phase 3

Novartis
Novartis

Westwood, Kansas, United States and 178 other locations

This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma...

Enrolling
Metastatic Melanoma
Unresectable Melanoma
Biological: IOV-4001

Phase 1, Phase 2

Iovance Biotherapeutics

Westwood, Kansas, United States and 8 other locations

combined with nivolumab in patients with unresectable or metastatic melanoma. A separate open-label cohort of adults with new, progressive b...

Active, not recruiting
Unresectable or Metastatic Melanoma
Progressive Brain Metastasis
Drug: Placebo in combination with nivolumab
Drug: HBI-8000 in combination with nivolumab

Phase 3

HUYABIO

Kansas City, Missouri, United States and 138 other locations

(GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other so...

Enrolling
Metastatic Uveal Melanoma
Cutaneous Melanoma
Drug: IDE196
Drug: Binimetinib

Phase 1, Phase 2

Ideaya Biosciences

Saint Joseph, Missouri, United States and 13 other locations

The primary objectives of this study are to:* Evaluate the safety and tolerability of AMG 355 as monotherapy and in combination with pembrolizumab in...

Enrolling
Advanced Solid Tumors
Drug: AMG 355
Drug: Pembrolizumab

Phase 1

Amgen
Amgen

Merriam, Kansas, United States and 18 other locations

This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several differ...

Enrolling
Melanoma
Squamous Cell Carcinoma of the Head and Neck
Drug: pembrolizumab
Drug: brentuximab vedotin

Phase 2

Seagen
Seagen

Kansas City, Kansas, United States and 34 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems